Recombinant human growth hormone (r-hGH) evaluated for severe fibromyalgia with growth axis dysfunction
Background
Fibromyalgia Syndrome (FMS) is a chronic pain condition often associated with neuroendocrine dysfunction, particularly involving the growth hormone (GH) axis. Patients with FMS frequently exhibit reduced GH secretion, which can contribute to symptoms like fatigue, pain, and impaired quality of life. Current treatments for FMS often provide incomplete relief, highlighting a need for therapies targeting underlying physiological imbalances. Recombinant human growth hormone (r-hGH) is being explored as a potential intervention to restore GH levels and alleviate FMS symptoms.
Study Design
This was an exploratory, randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT00497562). The study evaluated r-hGH (Saizen®) in severe fibromyalgia subjects with growth axis dysfunction. Participants were girls. The primary endpoint was to evaluate the efficacy and safety of r-hGH as an add-on treatment. The study completed in November 2005, but specific dosing, route, or duration details are not provided in the abstract.
Why It Matters
Investigating growth hormone axis dysfunction in fibromyalgia is crucial for identifying novel therapeutic targets beyond symptomatic relief. If r-hGH proves effective, it could offer a physiological approach to managing severe FMS, potentially improving core symptoms like pain and fatigue by addressing an underlying endocrine imbalance. This research highlights the ongoing exploration of peptides like r-hGH to modulate systemic physiology in chronic conditions where conventional treatments fall short. While specific outcomes are not detailed here, the focus on a biological mechanism suggests a path toward more targeted interventions for FMS patients.
fibromyalgia
growth-hormone
r-hgh
neuroendocrine
clinical-trial
phase-2